PRGO vs AMGN Stock Comparison: AI Score, Valuation, Performance and Upside
PRGO (Perrigo) is a private label OTC healthcare manufacturer serving the value-seeking end of the consumer health market, while AMGN (Amgen) is a major innovative biotechnology company developing premium branded biological medicines. These companies operate at opposite ends of the pharmaceutical value chain with very different margins, growth profiles, and risk characteristics.
PRGO vs AMGN contrasts the private-label generic pharmaceuticals and consumer health model against one of the world's largest innovative biotechnology companies, representing opposite ends of the pharmaceutical investment spectrum.
AMGN holds the edge across 3 of 5 key metrics in this comparison. AMGN has delivered stronger 1-year price return (+39.81% vs -36.58%), though PRGO has the better forward P/E setup (6.04x vs 15.46x for AMGN). AMGN leads on both revenue growth (9.50%) and operating margin (35.55%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for PRGO (+13.87%) than for AMGN (+2.83%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to the private label consumer health segment benefiting from retailer preference for higher-margin store brands
- See Perrigo's strategic refocus on consumer self-care as creating a cleaner, more focused business with recovery potential
- Value the recession-resilient nature of OTC consumer health spending as a defensive consumer staples-adjacent investment
- Want one of the largest, most diversified biotechnology companies with a growing portfolio across oncology, cardiovascular, and inflammation
- Value Amgen's durable free cash flow and consistent dividend payment as a quality large-cap biotechnology income investment
- See biosimilar revenue as an additional growth pillar alongside Amgen's branded innovative portfolio
| Metric | PRGO | AMGN |
|---|---|---|
| AI scorei | 24.4 | 49.6 |
| AI ranki | #3283 | #566 |
| Latest closei | $13.56 | $385.65 |
| 1M returni | -2.87% | -12.82% |
| 6M returni | +40.52% | +10.21% |
| 1Y returni | -36.58% | +39.81% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PRGO | AMGN |
|---|---|---|
| 1Y ago | $6.34K (-36.6%) started 2025-09-18 | $13.98K (+39.8%) started 2025-09-18 |
| 5Y ago | $3.13K (-68.7%) started 2021-09-20 | $22.96K (+129.6%) started 2021-09-20 |
| 10Y ago | $1.45K (-85.5%) started 2016-09-19 | $39.45K (+294.5%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | PRGO | AMGN |
|---|---|---|
| Market capi | $2B | $204.01B |
| Trailing P/Ei | N/A | 23.42 |
| Forward P/Ei | 6.04 | 15.46 |
| Price/Salesi | N/A | 4.57 |
| EV/Revenuei | 1.23 | 6.49 |
| Analyst targeti | $16.50 | $388.03 |
| Target upsidei | +13.87% | +2.83% |
| Metric | PRGO | AMGN |
|---|---|---|
| Revenue growthi | -3.20% | 9.50% |
| Earnings growthi | N/A | 64.90% |
| EPS growthi | N/A | +64.90% |
| FCF margini | +10.55% | +22.69% |
| Operating margini | 3.84% | 35.55% |
| Profit margini | -41.85% | 22.95% |
| ROIC proxyi | -48.75% | 91.47% |
| Return on equityi | -48.75% | 91.47% |
| Dividend yieldi | 8.04% | 2.64% |
| Payout ratioi | 10950.00% | 60.87% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.54 | 0.43 |
| Debt/equityi | 138.18 | 490.28 |
| Current ratioi | 2.32 | 1.37 |
| Quick ratioi | 1.09 | 0.95 |
Over the past year, PRGO and AMGN have moved barely in the same direction (correlation of 0.14), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PRGO | AMGN |
|---|---|---|---|
| 1Y | Growthi | -36.58% | +39.81% |
| CAGRi | -36.60% | +39.85% | |
| Volatilityi | 54.81% | 29.49% | |
| Sharpe ratioi | -0.64 | 1.14 | |
| Sortino ratioi | -0.89 | 1.78 | |
| Max drawdowni | 58.91% | 16.57% | |
| Current drawdowni | 39.76% | 13.17% | |
| Avg drawdowni | 39.52% | 5.63% | |
| Ulcer Indexi | 42.65% | 7.43% | |
| Max daily dropi | 25.21% | 10.08% | |
| Max wkly dropi | 30.59% | 15.03% | |
| 5Y | Growthi | -68.73% | +102.17% |
| CAGRi | -20.77% | +15.13% | |
| Volatilityi | 38.34% | 24.66% | |
| Sharpe ratioi | -0.53 | 0.51 | |
| Sortino ratioi | -0.74 | 0.77 | |
| Max drawdowni | 80.95% | 24.86% | |
| Current drawdowni | 72.08% | 13.17% | |
| Avg drawdowni | 40.49% | 8.13% | |
| Ulcer Indexi | 44.93% | 10.31% | |
| Max daily dropi | 25.21% | 10.08% | |
| Max wkly dropi | 30.59% | 15.03% | |
| 10Y | Growthi | -85.46% | +192.66% |
| CAGRi | -17.55% | +11.34% | |
| Volatilityi | 38.36% | 25.22% | |
| Sharpe ratioi | -0.43 | 0.37 | |
| Sortino ratioi | -0.57 | 0.55 | |
| Max drawdowni | 90.50% | 24.86% | |
| Current drawdowni | 86.08% | 13.17% | |
| Avg drawdowni | 53.25% | 8.22% | |
| Ulcer Indexi | 57.58% | 10.06% | |
| Max daily dropi | 29.28% | 10.08% | |
| Max wkly dropi | 35.26% | 15.79% |
| Category | PRGO | AMGN |
|---|---|---|
| Company | Perrigo Company plc | Amgen Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General |
| Core business | Perrigo is a leading manufacturer of store-brand (private label) OTC healthcare products and generic pharmaceuticals, producing consumer health products across pain relief, cough and cold, allergy, digestive health, and other categories for retailers to sell as their own-brand alternatives to national brands. | Amgen is one of the world's largest biotechnology companies, developing and marketing innovative biological medicines across oncology (Blincyto, Lumakras), cardiovascular (Repatha), inflammation (Enbrel, Otezla), and rare disease, while also building a biosimilars business. |
| Investor focus | Investors track Perrigo's consumer self-care segment revenue growth, generic pharmaceutical business performance, margins across its product mix, and the company's path to profitability improvement following its strategic refocus on consumer health. | Investors track Amgen's product revenue growth from newer products (Repatha, Otezla, Lumakras) offsetting mature product erosion (Enbrel biosimilar competition), pipeline success rates, and biosimilar revenue contribution from its own portfolio. |
- Private label OTC pharmaceuticals provide retailers with higher-margin alternatives to national brands — a structurally advantaged position as retailers prefer private label
- Scale in OTC manufacturing allows Perrigo to offer cost-efficient production for numerous consumer healthcare categories
- Consumer health is a resilient spending category — cold medicine, pain relievers, and allergy products are purchased through economic cycles
- Diversified portfolio across multiple therapeutic areas reduces single-product concentration risk
- Repatha cardiovascular and Otezla dermatology/inflammation provide multi-billion dollar growth platforms
- Horizon Therapeutics acquisition added rare disease assets including Tepezza (thyroid eye disease) as a high-value specialty franchise
- Generic OTC pharmaceutical pricing faces constant pressure from competition and retailer bargaining power
- Perrigo has undergone significant strategic restructuring and management changes, creating operational uncertainty
- Regulatory compliance in pharmaceutical manufacturing is complex and can be costly to maintain across its global facilities
- Enbrel faces biosimilar competition as market exclusivity expires, pressuring one of its historically largest revenue contributors
- Pipeline R&D success rates are inherently unpredictable — clinical trial failures can materially affect Amgen's near-term earnings outlook
- Pharmaceutical pricing pressure from government negotiation programs (IRA) could affect future drug pricing for Amgen's branded products
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.